Invasive Fungal Infections: The Impact of Host-, Organism-, and Treatment-Related Factors on Outcomes

EDUCATIONAL OVERVIEW
The management of invasive fungal infections (IFIs) has evolved immensely over the years, led by the development of a number of new antifungal agents and advanced diagnostic techniques that detect infections at early stages. The expanded use of antifungals (for prophylaxis, empiric or definitive treatment) has led to a global shift in etiology towards more infections caused by organisms less susceptible to commonly used antifungals. Despite advances in drug development, the incidence and mortality associated with IFIs have not changed substantially in the last 2 decades. This has led to a recent resurgence of updates to evidence-based practice guidelines for various types of fungal infections by the Infectious Diseases Society of America. Clinicians, including physicians, pharmacists, nurses, and other allied healthcare personnel, must understand and recognize these new developments in order to accurately diagnose, evaluate, prevent, and treat IFIs.

TARGET AUDIENCE
This activity is designed for Infectious Diseases physicians as well as other healthcare professionals on the frontline of managing patients with or at risk for invasive fungal infections.

LEARNING OBJECTIVES
Healthcare professionals participating in this educational activity will be able at its conclusion to:

Recognize the changing epidemiology of invasive fungal infections
Assess the latest diagnostic approaches for early detection of IFIs
Identify at-risk patients to guide antifungal prophylaxis
Select an appropriate antifungal agent based on evidence-based guideline recommendations and patient factors

EDUCATIONAL FORMAT
This webcast on demand is based on the CME Satellite Symposium which was held following the official programming of IDWeek 2012.

Episode 1: Understanding IFIs:
The Impact of Patient and Organism
Pranatharthi H. Chandrasekar, MD
Episode 2: Evolving Epidemiology of IFIs
Richard H. Drew, PharmD
Episode 3: Tools for Early Detection: Latest Diagnostic Approaches to Guide Antifungal Selection
Pranatharthi H. Chandrasekar, MD
Episode 4: Patient-Centered Approaches in Managing IFIs Series of Real-life Patient Cases with Evidence-based Support
Kieren A. Marr, MD

Note: If you have received credit for attending the live symposium
by the same name, you are not eligible to apply for credit for this
online version.

FACULTY

	Pranatharthi H. Chandrasekar, MD Professor of Medicine/Infectious Diseases Wayne State University School of Medicine Chief, Section of Infectious Diseases Karmanos Cancer Institute Detroit, MI

	Richard H. Drew, PharmD, MS, BCPS, FCCP Professor Campbell University College of Pharmacy & Health Sciences Associate Professor of Medicine (Infectious Diseases) Duke University School of Medicine Durham, NC

	Kieren A. Marr, MD Professor of Medicine Johns Hopkins School of Medicine Professor of Oncology Sidney Kimmel Comprehensive Cancer Center Director, Transplant and Oncology ID Baltimore, MD

ACCREDITATION

Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Center for Independent Healthcare Education and Vemco MedEd, LLC. Center for Independent Healthcare Education (Center) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Center for Independent Healthcare Education designates this Enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding the accreditation of this activity, please contact us at info@jointsponsor.com.

Method of Participation and Instructions for Credit

Review the entire CME information including target audience, learning objectives, and disclosures.
Review each episode.
Print and complete the Post Test, Evaluation, and Credit Application Form.
Please note that to receive credit you must achieve a score of at least 70%.
Mail the completed Post Test, Evaluation, and Credit Application Form to Vemco MedEd, 245 US Highway 22, Suite 304, Bridgewater, NJ 08807 or fax to (908) 235-4222 or email to bhassid@vemcomeded.com.

Documentation of credit will be mailed within 4 weeks of receipt of the completed Post Test, Evaluation, and Credit Application Form.

DISCLOSURE OF CONFLICTS OF INTEREST
In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity.

Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commerically-disinterested peer.

Planning Committee Members
Pranatharthi H. Chandrasekar, MD
Richard H. Drew, PharmD, MS, BCPS, FCCP
Kieren A. Marr, MD
Paul DeLisle
Marco Cicero, PhD
Maja Drenovac, PharmD

DISCLOSURE OF FINANCIAL INTEREST SUMMARY

Pranatharthi H. Chandrasekar, MD (Faculty/Planner) has relevant financial relationships with commercial interest as follows:

Advisory Board: Optimer, Astellas
Consultant: Pfizer, Astellas
Research Support: Merck, Chimerix, Astellas

Dr. Chandrasekar does not intend to discuss the off-label use of a product.

Richard H. Drew, PharmD, MS, BCPS, FCCP (Faculty/Planner) has relevant financial relationships with commercial interests as follows:

Consultant: Merck
Speakers Bureau: Merck
Research Support: Merck
Development Team: CustomID

Dr. Drew does not intend to discuss the off-label use of a product.

Kieren A. Marr, MD (Faculty/Planner) has relevant financial relationships with commercial interests as follows:

Advisory Board: Astellas, Merck, Optimer, Pfizer
Consultant: Astellas, Merck, Optimer, Pfizer
Grant Recipient/Research Support: Funds to JHMI, Astellas, Merck, Pfizer, Sigma Tau

Dr. Marr does not intend to discuss the off-label use of a product.

No (other) speakers, authors, planners or content reviewers have any relevant financial relationships to disclose. No (other) speakers or authors will discuss off-label use of a product.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Joint Sponsorship
This activity is jointly sponsored by
Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support
This activity is supported by an educational grant
from Astellas Scientific and Medical Affairs, Inc.

Fee
There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any "pop-up blocker" features.

Software/Hardware
Adobe® Reader version 7 or above to view PDF files
(If you do not have Adobe® Reader, you can download it for free from Adobe.com)
Adobe Flash Player version 10 or above to view multimedia content (If you do
not have Adobe Flash Player, you can download it for free from Adobe.com)

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to info@vemcomeded.com.

Privacy Policy
http://www.vemcomeded.com/privacy.asp

Please take a few moments to take the Pre-Activity Survey.